210 related articles for article (PubMed ID: 38100711)
21. FIGO staging system for endometrial cancer: added benefits of MR imaging.
Beddy P; O'Neill AC; Yamamoto AK; Addley HC; Reinhold C; Sala E
Radiographics; 2012; 32(1):241-54. PubMed ID: 22236905
[TBL] [Abstract][Full Text] [Related]
22. [Significance of prognostic evaluation of International Federation of Gynecology and Obstetrics 2009 staging system on stage I endometrioid adenocarcinoma].
Wang ZQ; Zhang Y; Wang JL; Shen DH; Mu T; Zhao X; Yao YY; Bai Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):33-9. PubMed ID: 22455691
[TBL] [Abstract][Full Text] [Related]
23. Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study.
Capriglione S; Plotti F; Miranda A; Ricciardi R; Scaletta G; Aloisi A; Guzzo F; Montera R; Angioli R
Tumour Biol; 2015 Jun; 36(6):4151-6. PubMed ID: 25577252
[TBL] [Abstract][Full Text] [Related]
24. Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies? Revised staging, endometrial cancer, histology.
Page BR; Pappas L; Cooke EW; Gaffney DK
Int J Gynecol Cancer; 2012 May; 22(4):593-8. PubMed ID: 22343970
[TBL] [Abstract][Full Text] [Related]
25. Aberrant TRPC1 expression reflects stromal cervical invasion, lymphovascular invasion, elevated FIGO stage, and poor survival in resectable endometrial carcinoma patients.
Wang Y; Zhang C
J Clin Lab Anal; 2022 Aug; 36(8):e24560. PubMed ID: 35754147
[TBL] [Abstract][Full Text] [Related]
26. FIGO staging of endometrial cancer: 2023.
Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
J Gynecol Oncol; 2023 Sep; 34(5):e85. PubMed ID: 37593813
[TBL] [Abstract][Full Text] [Related]
27. The role of magnetic resonance imaging in the evaluation of endometrial carcinoma.
Aracki-Trenkic A; Stojanov D; Petric A; Benedeto-Stojanov D; Trenkic M; Ignjatovic J
J BUON; 2016; 21(3):542-8. PubMed ID: 27569070
[TBL] [Abstract][Full Text] [Related]
28. Clinical value of DNA content assessment in endometrial cancer.
Mauland KK; Wik E; Salvesen HB
Cytometry B Clin Cytom; 2014 May; 86(3):154-63. PubMed ID: 24532190
[TBL] [Abstract][Full Text] [Related]
29. The Significance of International Federation of Gynecology and Obstetrics Grading in Microsatellite Instability-High and POLE-Mutant Endometrioid Endometrial Carcinoma.
Kertowidjojo E; Momeni-Boroujeni A; Rios-Doria E; Abu-Rustum N; Soslow RA
Mod Pathol; 2023 Sep; 36(9):100234. PubMed ID: 37268062
[TBL] [Abstract][Full Text] [Related]
30. Endometrial Cancer: An Update on Prognostic Pathologic Features and Clinically Relevant Biomarkers.
Li JJX; Ip PPC
Surg Pathol Clin; 2022 Jun; 15(2):277-299. PubMed ID: 35715162
[TBL] [Abstract][Full Text] [Related]
31. Endometrial Cancer, the Current International Federation of Gynecology and Obstetrics Staging System, and the Role of Imaging.
Saleh M; Virarkar M; Bhosale P; Elsherif S; Javadi S; Faria SC
J Comput Assist Tomogr; 2020; 44(5):714-729. PubMed ID: 32842057
[TBL] [Abstract][Full Text] [Related]
32. Estimated intermediate risk endometrial cancer: debate and new perspectives on therapy individualization and prognosis establishment starting from a peculiar case.
Gizzo S; Fabris A; Litta P; Saccardi C
Int J Clin Exp Pathol; 2014; 7(5):2664-9. PubMed ID: 24966983
[TBL] [Abstract][Full Text] [Related]
33. Dynamic contrast-enhanced ultrasound improves diagnostic performance in endometrial cancer staging.
Green RW; Epstein E
Ultrasound Obstet Gynecol; 2020 Jul; 56(1):96-105. PubMed ID: 31647145
[TBL] [Abstract][Full Text] [Related]
34. Upgrading Treatment and Molecular Diagnosis in Endometrial Cancer-Driving New Tools for Endometrial Preservation?
Dellino M; Cerbone M; Laganà AS; Vitagliano A; Vimercati A; Marinaccio M; Baldini GM; Malvasi A; Cicinelli E; Damiani GR; Cazzato G; Cascardi E
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298731
[TBL] [Abstract][Full Text] [Related]
35. Mutation status coupled with RNA-sequencing data can efficiently identify important non-significantly mutated genes serving as diagnostic biomarkers of endometrial cancer.
Liu K; He L; Liu Z; Xu J; Liu Y; Kuang Q; Wen Z; Li M
BMC Bioinformatics; 2017 Dec; 18(Suppl 14):472. PubMed ID: 29297280
[TBL] [Abstract][Full Text] [Related]
36. [Histological and molecular classification of endometrial carcinoma and therapeutical implications].
Genestie C; Leary A; Devouassoux M; Auguste A
Bull Cancer; 2017 Dec; 104(12):1001-1012. PubMed ID: 29031505
[TBL] [Abstract][Full Text] [Related]
37. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
Rios-Doria E; Momeni-Boroujeni A; Friedman CF; Selenica P; Zhou Q; Wu M; Marra A; Leitao MM; Iasonos A; Alektiar KM; Sonoda Y; Makker V; Jewell E; Liu Y; Chi D; Zamarin D; Abu-Rustum NR; Aghajanian C; Mueller JJ; Ellenson LH; Weigelt B
Gynecol Oncol; 2023 Jul; 174():262-272. PubMed ID: 37245486
[TBL] [Abstract][Full Text] [Related]
38. The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered?
Abu-Rustum NR; Zhou Q; Iasonos A; Alektiar KM; Leitao MM; Chi DS; Sonoda Y; Soslow R; Hensley M; Barakat RR
Int J Gynecol Cancer; 2011 Apr; 21(3):511-6. PubMed ID: 21436699
[TBL] [Abstract][Full Text] [Related]
39. Development and Validation of a Five-immune Gene Pair Signature in Endometrial Carcinoma.
Li N; Yu K; Lin Z; Zeng D
Comb Chem High Throughput Screen; 2021; 24(2):233-245. PubMed ID: 32729416
[TBL] [Abstract][Full Text] [Related]
40. Molecular approaches for classifying endometrial carcinoma.
Piulats JM; Guerra E; Gil-MartÃn M; Roman-Canal B; Gatius S; Sanz-Pamplona R; Velasco A; Vidal A; Matias-Guiu X
Gynecol Oncol; 2017 Apr; 145(1):200-207. PubMed ID: 28040204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
